COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > Perplexity Ai: The conclusion...

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Aug 29, 2024 9:40pm

45 Views

Post# 36202201

RE:RE:RE:RE:Perplexity Ai: The conclusion...

Hopeforthebest, "gagnon's credit ability with at least Canadian shareholders is zilch. He has made statements, timelines etc without ever delivering."

Canadian pharmaceutical icon Ronald W. Miller, Chair of the Company:

“With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.” June 3, 2024

“We are very pleased with the ongoing post-merger integration process and expect to be providing a fulsome update shortly." Gilles Gagnon Aug. 13, 2024

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project